Adaptin Bio, Inc. (OTCPK: APTN)
Health Care · Biotechnology · US
$6.27
— today · +12.0% 1Y
Adaptin Bio, Inc. (OTCPK: APTN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $56.40M.
Over the last twelve months the share price has gained 12.0%, trading between 5.60 and 6.27.
Tweenvest scores Adaptin Bio, Inc. across four factors: quality 12/100. Its strongest factor is quality.
APTN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $56.40M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.67
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $6.27
- 52-week low
- $5.60
- Avg volume (3M)
- —
- Shares outstanding
- 9.00M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.80 | +0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.00 | +0.40% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.51 | -2.09% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.